Related Articles
A phase II, randomized study of aprepitant in the prevention of chemotherapy‑induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients
5-HT3 ANTAGONIST ONDANSETRON FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN AN OUTPATIENT POPULATION
Comparison between the antiemetic effects of palonosetron and granisetron in breast cancer patients treated with anthracycline‑based regimens
Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti‑emetic treatment with aprepitant and fosaprepitant: A retrospective comparison
Palonosetron exhibits higher total control rate compared to first‑generation serotonin antagonists and improves appetite in delayed‑phase chemotherapy‑induced nausea and vomiting